Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yusuke Tanetsugu"'
Autor:
Naoto Takahashi, Jorge E. Cortes, Emiko Sakaida, Kenichi Ishizawa, Takaaki Ono, Noriko Doki, Itaru Matsumura, Valentín García-Gutiérrez, Gianantonio Rosti, Chiho Ono, Masayuki Ohkura, Yusuke Tanetsugu, Andrea Viqueira, Tim H. Brümmendorf
Publikováno v:
International Journal of Hematology. 115:838-851
Bosutinib has been investigated in multiple clinical trials globally, including Japan, for treatment of chronic myeloid leukemia (CML). A pooled analysis of seven Pfizer-sponsored clinical trials evaluated the safety of bosutinib in Japanese (n = 138
Autor:
Takaaki Ono, Masayuki Hino, Itaru Matsumura, Shin Fujisawa, Kenichi Ishizawa, Emiko Sakaida, Naohiro Sekiguchi, Chiho Ono, Mana Aizawa, Yusuke Tanetsugu, Yuichiro Koide, Naoto Takahashi
Publikováno v:
International journal of hematology. 116(6)
Bosutinib has been evaluated for treatment of chronic-phase chronic myeloid leukemia (CP-CML) in several clinical studies, including in Japan. This open-label, single-arm, phase 2 study evaluated the efficacy and safety of bosutinib at a starting dos
Autor:
Takaaki Ono, Yusuke Tanetsugu, Shin Fujisawa, Itaru Matsumura, Yuichiro Koide, Emiko Sakaida, Naohiro Sekiguchi, Mana Aizawa, Naoto Takahashi, Chiho Ono, Masayuki Hino, Kenichi Ishizawa
Publikováno v:
Blood. 138:2557-2557
Introduction : Bosutinib is approved in Japan for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and Ph+ CML resistant/intolerant to prior therapy. In the primary report of a pha
Autor:
Masayuki Ohkura, Masayuki Hino, Naohiro Sekiguchi, Naoto Takahashi, Itaru Matsumura, Emiko Sakaida, Kenichi Ishizawa, Yuichiro Koide, Shin Fujisawa, Yusuke Tanetsugu, Takaaki Ono, Kei Fukuhara
Publikováno v:
Blood. 134:4159-4159
Background: Bosutinib, a Src/Abl tyrosine kinase inhibitor, is approved at a starting dose of 500 mg once daily (QD) in many countries, including Japan, for patients with Philadelphia chromosome-positive (Ph+) chronic phase (CP), accelerated phase (A
Autor:
Masato Ohta, Takayuki Terukina, Tatsuaki Tagami, Takaya Ogawa, Yusuke Tanetsugu, Tetsuya Ozeki
Publikováno v:
Biologicalpharmaceutical bulletin. 40(2)
Ranibizumab is a humanized monoclonal antibody fragment against vascular endothelial growth factor (VEGF)-A and is widely used to treat age-related macular degeneration (AMD) caused by angiogenesis. Ranibizumab has a short half-life in the eye due to